A meta‐analysis of 19 randomized controlled trials (RCTs) (155,027 patients with type 2 diabetes) found that compared with a placebo, glucagon‐like peptide‐1 (GLP‐1) agonists reduced nonfatal stroke by 15% and stroke incidence by 16% [118]. This evidence concerns the gene GLP1R and stroke disorder.